Publication: Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer
Date
Authors
Canhoroz, Mustafa
Ölmez, Ömer Fatih
Kanat, Özkan
Kurt, Ender
Erol, Muharrem
Yorulmaz, Nadide
Authors
Çubukcu, Erdem
Canhoroz, Mustafa
Ölmez, Ömer Fatih
Kanat, Özkan
Kurt, Ender
Erol, Muharrem
Çubukcu, Sinem
Yorulmaz, Nadide
Bayram, Sami
Evrensel, Türkkan
Advisor
Language
Type
Publisher:
Derman Medical Publ
Journal Title
Journal ISSN
Volume Title
Abstract
Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.
Description
Source:
Keywords:
Keywords
Nonsmall cell lung cancer, Adjuvant chemotherapy, Cisplatin, General & internal medicine